Holen Sie sich die Stockscreener-App
0.273
7.91%
0.02
Handel nachbörslich:
.27
-0.003
-1.10%
Schlusskurs vom Vortag:
$0.253
Offen:
$0.247
24-Stunden-Volumen:
2.67M
Relative Volume:
1.00
Marktkapitalisierung:
$28.56M
Einnahmen:
$297.50K
Nettoeinkommen (Verlust:
$-72.19M
KGV:
-0.1594
EPS:
-1.7127
Netto-Cashflow:
$-54.39M
1W Leistung:
+9.16%
1M Leistung:
-30.71%
6M Leistung:
-81.30%
1J Leistung:
-80.36%
1-Tages-Spanne:
$0.247
$0.276
1-Wochen-Bereich:
$0.21
$0.276
52-Wochen-Spanne:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.273 | 26.47M | 297.50K | -72.19M | -54.39M | -1.7127 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Breakouts Watch: Will Outlook Therapeutics Inc benefit from AI trends2026 Big Picture & Low Drawdown Trading Strategies - baoquankhu1.vn
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga
H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Hold Rating, Maintains Target Price $0.5 - Moomoo
Outlook Therapeutics files dispute resolution request with FDA By Investing.com - Investing.com India
Outlook Therapeutics’ Formal Dispute Resolution for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA for Wet AMD Approval Pathway 1 - Minichart
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA - Sahm
Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug - Sahm
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010 - TipRanks
FDA accepts Outlook Therapeutics (NASDAQ: OTLK) dispute request on LYTENAVA - Stock Titan
Outlook Therapeutics request for FDA dispute resolution on ONS-5010 accepted - Traders Union
Outlook Therapeutics (OTLK) Seeks FDA Review for ONS-5010 Approval - GuruFocus
Outlook Therapeutics files dispute resolution request with FDA - Investing.com
Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA - TradingView — Track All Markets
FDA accepts Outlook dispute request, sets April eye-drug meeting - Stock Titan
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA - Bitget
Outlook Therapeutics (OTLK) price target decreased by 27.91% to 3.95 - msn.com
Outlook Therapeutics, Inc. (OTLK) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Outlook Therapeutics (XTER:41O) PE Ratio : N/A (As of Apr. 04, 2026) - GuruFocus
Outlook Therapeutics (XTER:41O) PB Ratio : (As of Apr. 04, 2026) - GuruFocus
Live Outlook Therapeutics, Inc. (OTLK) Technical Analysis - Traders Union
Is Outlook Therapeutics Inc a top pick in the sectorEarnings Risk Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Outlook Therapeutics Inc (41O.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
OTLK SEC FilingsOutlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
OTLK Technical Analysis & Stock Price Forecast - Intellectia AI
Institution Moves: Will Outlook Therapeutics Inc outperform the market in YEAR2026 Gainers & Long-Term Capital Growth Strategies - baoquankhu1.vn
Outlook Therapeutics (OTLK) Price Target Increased by 11.90% to 9.59 - msn.com
Can Outlook Therapeutics Inc reach all time highs this year2026 Bull vs Bear & Comprehensive Market Scan Insights - baoquankhu1.vn
Why Is OTLK Stock Falling Today? - Stocktwits
Profit Recap: Is Outlook Therapeutics Inc stock a buy or sell2026 Technicals & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants - The Globe and Mail
Outlook Therapeutics closes $5 million stock offering By Investing.com - Investing.com Australia
Published on: 2026-03-26 16:05:05 - baoquankhu1.vn
Outlook Therapeutics Announces $500,000 Public Offering of Common Stock and Warrants - Minichart
Outlook Therapeutics closes 5.0 million dollar public offering to boost capital - Traders Union
Outlook Therapeutics commences $5.0M best-efforts offering of common stock with 1-for-1 warrants - TradingView — Track All Markets
[8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan
Outlook Therapeutics closes $5 million stock offering - Investing.com
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering - The Manila Times
Outlook Therapeutics (OTLK) launches 20M-share offering with detachable warrants - Stock Titan
Outlook Therapeutics prices $5M stock offering at $0.25 per share - au.investing.com
Outlook Therapeutics Announces Proposed Public Offering - Sahm
Outlook Therapeutics stock prices $5M offering at $0.25 per share amid Nasdaq plunge and biotech fun - AD HOC NEWS
Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced - marketscreener.com
Why is OTLK stock falling today? - MSN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering - ChartMill
Biggest stock movers Tuesday: CLB, OTLK, and more (NASDAQ:NTGR) - Seeking Alpha
Outlook Therapeutics launches public stock offering By Investing.com - ca.investing.com
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):